



Notification Date: 30 June 2025

MMR Testing

Recent evidence on neoadjuvant immune checkpoint inhibitors (ICI) therapy in colonic and rectal cancer requires that testing be performed on biopsy tissue, before surgery. MMR testing on biopsy tissue has important advantages as it enables clinicians to tailor treatment to the patient's cancer with a rapid (and pre-surgical) evaluation of MMR status. (Grillo et al. 2023)

Going forward, SBMF will conduct an evaluation of MMR status on all colorectal biopsies with a positive colorectal adenocarcinoma diagnosis in any region. If the biopsy yields insufficient tissue for MMR testing, MMR testing will be repeated on the resection.

1. Grillo F, Paudice M, Gambella A, Bozzano S, Sciallero S, Puccini A, Lastraioli S, Dono M, Parente P, Vanoli A, Angerilli V, Fassan M, Mastracci L. Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens. *Histochem Cell Biol.* 2023 Aug;160(2):113-125. doi: 10.1007/s00418-023-02202-8. Epub 2023 Jun 7. PMID: 37284845; PMCID: PMC10386921.

Questions: Please contact Client Support at 574-236-7263